| Name | Title | Contact Details |
|---|
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Sagamore Health Network, Inc. is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Huntington Medical Research Insitutes is a Pasadena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gaylord Hospital was founded in 1902 as a tuberculosis sanatorium and provided long-term treatment during the 50 years when the disease was epidemic.
Arizona State Physicians Association (ASPA) is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.